Tanios S. Bekaii-Saab, MD

Tanios S. Bekaii-Saab, MD, is the leader of the Gastrointestinal Cancer Program at the Mayo Clinic Comprehensive Cancer Center; as well as medical director of the Cancer Clinical Research Office and vice chair and section chief for Medical Oncology in the Department of Internal Medicine at Mayo Clinic

Articles

Dr Bekaii-Saab on the Expanding Targeted Therapy Paradigm for Biliary Tract Cancers

July 14th 2025

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

Future Directions: Optimizing Care Through Combinations

November 1st 2022

Tanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.

Novel Investigational Combination Strategies

November 1st 2022

Tanios S. Bekaii-Saab, MD, provides insight into ongoing research exploring novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors across solid tumors.

Vigilance Is Key in Mitigating TKI-Associated Hepatotoxicity

October 25th 2022

Liver injury can occur within 2 weeks of starting therapy with a tyrosine kinase inhibitor, although it can also be seen as late as 2 months, describes Tanios S. Bekaii-Saab, MD, making vigilance key for proper mitigation of this adverse event.

Understanding and Detecting TKI-Specific Hepatotoxicity

October 18th 2022

Tanios S. Bekaii-Saab, MD, describes the hepatotoxicity commonly seen with tyrosine kinase inhibitors (TKIs) and how to monitor and detect it with aspartate aminotransferase (AST) and alanine transaminase (ALT).

Overview of Toxicity Associated With TKIs in Solid Tumors

October 18th 2022

Tanios S. Bekaii-Saab, MD, describes the common adverse events associated with each type of tyrosine kinase inhibitor (TKI), which are specific to the targets hit by that TKI and commonly include fatigue and hepatotoxicity.

Patient Profile 2: Frontline Therapy for Advanced HCC

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

Dr. Bekaii-Saab on Safety Profile of Tucatinib/Trastuzumab in HER2-Amplified mCRC

October 11th 2019

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.